Erasca priced an upsized public offering of 22,500,000 shares at $10.00 per share, expected to generate about $225 million in gross proceeds to fund its clinical‑stage RAS/MAPK oncology programs. The company also granted underwriters a 30‑day option for an additional 3,375,000 shares and said the offering should close Jan. 23. The transaction follows an earlier filing that proposed a $150 million offering; management cited market conditions and program funding needs in expanding the sale. The financing will back ongoing trials and platform work targeting RAS‑driven cancers and provides runway for upcoming clinical milestones that investors will watch closely.